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Abstract
Background–Dimethyl lithospermate B (dmLSB) is an extract of Danshen, a traditional Chinese
herbal remedy, which slows inactivation of INa, leading to increased inward current during the early
phases of the action potential (AP). We hypothesized that this action would be antiarrhythmic in the
setting of Brugada syndrome.
Methods and Results–The Brugada syndrome phenotype was created in canine arterially perfused
right ventricular wedge preparations with the use of either terfenadine or verapamil to inhibit INa and
ICa or pinacidil to activate IK-ATP. AP recordings were simultaneously recorded from epicardial and
endocardial sites together with an ECG. Terfenadine, verapamil, and pinacidil each induced all-or-
none repolarization at some epicardial sites but not others, leading to ST-segment elevation as well
as an increase in both epicardial and transmural dispersions of repolarization (EDR and TDR,
respectively) from 12.9±9.6 to 107.0±54.8 ms and from 22.4±8.1 to 82.2±37.4 ms, respectively
(P<0.05; n=9). Under these conditions, phase 2 reentry developed as the epicardial AP dome
propagated from sites where it was maintained to sites at which it was lost, generating closely coupled
extrasystoles and ventricular tachycardia and fibrillation. Addition of dmLSB (10 μmol/L) to the
coronary perfusate restored the epicardial AP dome, reduced EDR and TDR to 12.4±18.1 and 24.4
±26.7 ms, respectively (P<0.05; n=9), and abolished phase 2 reentry-induced extrasystoles and
ventricular tachycardia and fibrillation in 9 of 9 preparations.
Conclusions–Our data suggest that dmLSB is effective in eliminating the arrhythmogenic substrate
responsible for the Brugada syndrome and that it deserves further study as a pharmacological adjunct
to implanted cardioverter/defibrillator usage.
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The Brugada syndrome is a familial disease with an autosomal dominant mode of inheritance.
It is characterized by ST-segment elevation in the right precordial leads and episodes of syncope
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and sudden cardiac death. To date, >100 mutations in SCN5A, the gene that encodes for the
α-subunit of the cardiac sodium channel, have been linked to the syndrome (for review, see
Antzelevitch et al,1 Priori et al,2 Antzelevitch,3 Balser,4 and Tan5). All known mutations result
in a loss of sodium channel function.
Using the canine arterially perfused right ventricular wedge, our laboratory elucidated the
mechanisms responsible for ST-segment elevation in the right precordial leads and the
generation of lethal arrhythmias.6,7 The prominent transient outward current (Ito)-mediated
notch in the action potential (AP) of the right ventricular epicardium plays a pivotal role in the
arrhythmogenesis of the syndrome. A negative shift in the balance of currents active at the end
of phase 1, namely, sodium current (INa), calcium current (ICa), and Ito, can result in all-or-
none repolarization at the end of phase 1 (loss of the dome) in some areas of the epicardium
but not the endocardium, leading to ST-segment elevation. As the dome propagates from
regions where it is maintained to regions where it is lost, phase 2 reentry develops and gives
rise to an extrasystole that precipitates polymorphic ventricular tachycardia and fibrillation
(VT/VF). Ito block, via its actions to restore the AP dome and suppress phase 2 reentry and
VT/VF, has been suggested as a therapeutic strategy for the Brugada syndrome.6-10
In the present study we explore a novel therapeutic strategy for the Brugada syndrome by
selectively enhancing sodium current with dimethyl lithospermate B (dmLSB), a minor
component of the root extract from Salvia miltiorrhiza. Previous studies with dmLSB have
demonstrated a slowing of inactivation of INa without an increase in persistent late INa.11 We
hypothesized that this action of dmLSB will prevent loss of the epicardial AP dome and be
effective in preventing phase 2 reentry and VT/VF in the Brugada syndrome. To test this
hypothesis, we examined the actions of dmLSB in 3 distinct pharmacological models of the
Brugada syndrome.
Methods
The detailed methods used for isolation, perfusion, and recording of transmembrane activity
from the arterially perfused canine right ventricular wedge preparation, as well as the viability
and electric stability of the preparation, have been previously reported.6,12 Experiments
demonstrating that activity recorded from the cut surface of the perfused wedge preparation is
representative of cells within the respective layers of the wall throughout the wedge have also
been reported in a number of previous studies.12-14
Briefly, transmural wedge preparations with dimensions of ≈2×1×0.9 to 3.0×1.5×1.2 cm were
dissected from the right ventricle of male and female random-source 20- to 35-kg canines. The
preparations were cannulated via a small (diameter ≈100 to 150 μm) coronary artery (a
descending branch of the right coronary artery) and perfused with cardioplegic solution
(Tyrode’s containing 12 mmol/L KCl). Unperfused tissue was carefully removed with a razor
blade. The preparations were then placed in a small tissue bath and arterially perfused with
Tyrode’s solution. The temperature of the coronary perfusate was maintained at 35±0.5°C. The
perfusate was delivered to the artery by a roller pump (Cole Parmer Instrument Co, Niles, Ill).
Perfusion pressure was monitored with a pressure transducer (World Precision Instruments,
Inc, Sarasota, Fla) and maintained between 40 and 50 mm Hg by adjustment of the perfusion
flow rate.
The wedge preparations were equilibrated in the tissue bath until electrically stable, usually 1
to 2 hours. The preparations were continuously stimulated at a basic cycle length (BCL) of
2000 ms with the use of bipolar silver electrodes insulated except at the tips and applied to the
endocardial surface. To induce loss of the epicardial AP dome and phase 2 reentry, the
preparations were paced at BCLs ranging from 200 to 5000 ms. A transmural ECG was
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recorded with electrodes consisting of 2 AgCl half cells placed in the Tyrode’s solution bathing
the preparation, 1.0 to 1.5 cm from the epicardial and endocardial surfaces of the preparation,
along the same axis as the transmembrane recordings (epicardium: “+” pole). Transmembrane
APs were simultaneously recorded from 2 epicardial and 1 endocardial site with the use of
floating microelectrodes (DC resistance=10 to 20 mol/LΩ) filled with 2.7 mol/L KCl, each
connected to a high-input impedance amplifier. Impalements were obtained from the epicardial
and endocardial surfaces of the preparation at positions approximating the transmural axis of
the ECG recording. When 2 simultaneous epicardial impalements were recorded, the one with
the longer action potential duration (APD) was designated Epi 1, and the other was designated
Epi 2.
Isolation of dmLSB From the Root Extract of S miltiorrhiza
Dried roots of S miltiorrhiza (6 kg) were soaked in MeOH for 7 days at room temperature.
After filtration, the extract was concentrated under the reduced pressure to give 470 g of a dark
syrupy MeOH extract. This was suspended in H2O and sequentially partitioned with n-hexane,
EtOAc, and BuOH. This process yielded 69 g in the n-hexane fraction, 52 g in the EtOAc
fraction, 69 g in the BuOH fraction, and a water-soluble residue. Half of the EtOAc fraction
(26 g) was subjected to octadecyl silica gel column ( 6.0 × height 60 cm) chromatography. The
column was eluted in a stepwise gradient manner with 300-mL aliquots of MeOH in H2O (0%
to 100%), which delivered 4 fractions: fraction 1 (3.2 g), fraction 2 (13 g), fraction 3 (2.4 g),
and fraction 4 (7.0 g). Among these fractions (fraction 1 to fraction 4), fraction 2 was the most
potent and was further purified by Sephadex LH-20 column chromatography with the use of
20% MeOH in CH2Cl2, which finally delivered 110 mg of dmLSB and 2.4 g of LSB. Moreover,
LSB was easily converted to dmLSB by simple methylation of LSB in MeOH with the use of
p-toluenesulfonic acid as catalyst. The chemical structure of dmLSB was elucidated with the
use of 1H-NMR and 13C-NMR data.15 A stock solution of 20 mmol/L dmLSB was prepared
in 100% dimethyl sulfoxide. The wedge preparations were exposed to dmLSB for a period of
30 minutes.
Statistical Analysis
Statistical analysis was performed with the use of 1-way ANOVA or Kruskal-Wallis ANOVA
on ranks in combination with a Tukey test, as appropriate. Incidence data were analyzed with
a Fisher exact test. All data are reported as mean±SD.
The authors had full access to the data and take responsibility for its integrity. All authors have
read and agree to the manuscript as written.
Results
An inward shift in the balance of current active during the early phases of the right ventricular
AP underlies the ECG and arrhythmic manifestations of the Brugada syndrome. In the right
ventricular wedge preparation, such a shift can be achieved with the use of either agents that
inhibit inward depolarizing current or agents that activate outward repolarizing current. We
created the Brugada phenotype using both approaches. Verapamil was used to block inward
calcium channel current (ICa), pinacidil to activate adenosine triphosphate (ATP)-sensitive
outward potassium current (IK-ATP), and terfenadine to block both inward sodium current
(INa) and ICa. Figure 1 shows tracings recorded from arterially perfused wedge preparations
before and after the addition of terfenadine, verapamil, or pinacidil. Each agent increased the
magnitude of the epicardial AP notch, leading to the appearance of a more pronounced ECG
J wave. The characteristics of the AP notch are summarized in Figure 2 and Table 1.
Terfenadine, verapamil, or pinacidil significantly increased the phase 0 to phase 2 interval as
well as the notch index, which approximates the area of the notch. dmLSB (10 μmol/L) in the
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continued presence of terfenadine, verapamil, or pinacidil significantly reduced the notch
magnitude, phase 0 to phase 2 interval, and notch index toward control values.
Figure 3 and Table 2 show APD measured at 90% repolarization (APD90) at steady state
(BCL=2000 ms) for each of the 3 Brugada syndrome models. Pinacidil abbreviated APD90,
whereas terfenadine and verapamil tended to prolong it, largely secondary to accentuation of
the AP notch. Consistent with its effect to increase INa during the early but not late phases of
the AP, dmLSB tended to abbreviate APD90, secondary to diminution of the AP notch.
Heterogeneous loss of the epicardial AP dome occurred in the presence of terfenadine,
verapamil, or pinacidil, generating both local epicardial dispersion of repolarization (EDR)
and transmural dispersion of repolarization (TDR) between the briefest epicardial response
and that of endocardium. EDR and TDR values for each of the 3 Brugada syndrome models
are summarized in Figure 4 and Table 3. With each treatment as well as with the combined
data, EDR and TDR increased compared with control, although the increase in TDR did not
reach statistical significance in the case of pinacidil. The addition of dmLSB (10 μmol/L)
resulted in a significant decrease in EDR and TDR toward control values.
Figures 5 and 6 illustrate heterogeneous loss of the epicardial AP dome and phase 2 reentry in
each of the 3 Brugada syndrome models. Phase 2 reentry occurred as the dome propagated
from regions of the epicardium where it was maintained to regions at which it was lost. This
mechanism generated closely coupled extrasystoles in all 9 preparations as well as polymorphic
VT in 6 of 9 wedge preparations. Addition of dmLSB (10 μmol/L) abolished phase 2 reentry
and all arrhythmic activity in 9 of 9 preparations (P<0.05 versus terfenadine, verapamil, or
pinacidil; Table 3).
The effects of dmLSB (0.5 to 20 μmol/L) alone in the canine arterially perfused right ventricular
wedge are illustrated in Figure 7. There was a concentration-dependent reduction in the size
of the epicardial AP notch, although this did not reach statistical significance. APD and
transmural dispersion were largely unaffected by dmLSB.
Discussion
Our study demonstrates for the first time that delaying the inactivation of INa by as little as 20
ms can prevent the ECG and arrhythmic manifestations of the Brugada syndrome in our
experimental models irrespective of the mechanism responsible for precipitating the disease.
dmLSB is shown to prevent the development of all-or-none repolarization, phase 2 reentry,
and the resultant closely coupled extrasystoles and polymorphic tachycardia in 3 different
experimental models that mimic the Brugada syndrome. These data suggest that dmLSB may
be a viable pharmacological alternative for the treatment of patients with the Brugada
syndrome, as an adjunct to the use of implanted cardioverter/defibrillators (ICDs),16 or as an
alternative in cases in which ICDs are not feasible or affordable.
dmLSB has previously been reported to slow the inactivation kinetics of INa by increasing the
proportion of the slowly inactivating component, raising the possibility that it would prolong
APD and QT interval, like ATX-II.17 Previous studies in rat ventricular myocytes demonstrate
that inactivation of INa was complete within 50 ms after 10 μmol/L dmLSB, resulting in no
increase in late INa.11 In the present study, dmLSB alone had no significant effect on APD90
or TDR up to a dose of 20 μmol/L, suggesting no proarrhythmic effects of the drug (Figure 7).
A delicate balance of inward and outward currents determines the voltage at the end of
epicardial AP phase 1. The 3 principal currents active at this point are INa, ICa, and Ito. Any
manipulation resulting in a negative shift in the balance of these 3 currents at the end of
epicardial AP phase 1 can result in an accentuated J wave as the epicardial AP notch becomes
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accentuated or ST-segment elevation as all-or-none repolarization at the end of epicardial phase
1 occurs. Terfenadine blocks late INa and ICa with an IC50 in canine ventricular myocytes of
1.3 and 1.1 μmol/L, respectively (A.C. Zygmunt, PhD, and C. Antzelevitch, PhD, unpublished
data, 2001). Terfenadine also produces both tonic and use-dependent block of INa, as was
demonstrated in canine atrial myocytes.18 These effects of terfenadine make the epicardial AP
notch more prominent by shifting the end of epicardial phase 1 to more negative voltages and
delaying the onset of phase 2 (Figure 1A). This model of the Brugada syndrome was described
and characterized in 2004.7 Similarly, verapamil inhibits ICa and late INa with an IC50 in canine
ventricular myocytes of 0.31 and 0.21 μmol/L, respectively (A.C. Zygmunt, PhD, and C.
Antzelevitch, PhD, unpublished data, 2001), resulting in a more prominent AP notch in the
epicardium (Figure 1B). Verapamil has been shown in one clinical case to create a Brugada-
like phenotype.19 This model of the Brugada syndrome has also been previously described.
7 Pinacidil activates the normally quiescent ATP-sensitive potassium current (IK-ATP),
resulting in a more pronounced epicardial AP notch (Figure 1C). The pinacidil model of the
Brugada syndrome was first described in 1999.6 In all 3 models, the AP notch was significantly
diminished after addition of dmLSB (10 μmol/L; Figures 1 and 2) because of the drug’s ability
to slow the inactivation kinetics of INa, resulting in a positive shift in the balance of currents
active at the end of epicardial AP phase 1. This was quantified by taking the amplitude
difference between phases 1 and 2 (notch magnitude) as well as the interval between phase 0
and phase 2. The notch magnitude was normalized to the amplitude of phase 2 to account for
the variable amplitude of the floating microelectrode impalement recordings.
The terfenadine-, verapamil-, or pinacidil-induced outward shift of current active during phase
1 of the AP leads to all-or-none repolarization at the end of phase 1 (loss of the dome) at some
epicardial sites but not others, generating a local EDR as well as a TDR (Figure 4). These
dispersions of repolarization and refractoriness create a vulnerable window for the generation
of reentrant arrhythmias. Propagation of the epicardial AP dome from regions in which it is
maintained to regions in which it is lost generates a closely coupled phase 2 reentrant
extrasystole that captures the vulnerable window leading to the development of closely coupled
extrasystoles and polymorphic VT (Figures 5 and 6). dmLSB (10 μmol/L) significantly reduces
both TDR and EDR in our models of the Brugada syndrome by preventing heterogeneous loss
of the epicardial AP dome and resulting AP abbreviation, secondary to an outward shift in the
balance of currents active during phase 1 of the AP. This action of the drug effectively
eliminated both the trigger and the substrate for reentry in 9 of 9 preparations tested.
Although all mutations thus far associated with the Brugada syndrome have been linked to
SCN5A, mutations in this gene account for ≈20% of Brugada syndrome cases,20 suggesting
the likelihood that genetic defects linked to other ion channel currents active during the early
phases of the AP may be involved, including Ito, IK-ATP, IKr, IKs, or ICa. The effectiveness of
dmLSB in preventing Brugada syndrome induced in these 3 diverse pharmacological models
suggests that this strategy may be effective in patients with Brugada syndrome induced by
various etiologies.
Previous studies from our laboratory suggest block of Ito as a therapeutic strategy for the
Brugada syndrome (for review, see Antzelevitch and Fish10). Both Ito block and delay in the
inactivation of INa with dmLSB result in a positive shift in the balance of currents active at the
end of epicardial AP phase 1, making loss of the epicardial AP dome and phase 2 reentry
unlikely.
ICD implantation is the mainstay of therapy for the Brugada syndrome. Although feasible,
implantation is challenging in infants and is not an adequate solution for patients residing in
regions of the world where an ICD is unaffordable. A pharmacological solution is desirable as
an alternative to device therapy in these cases as well as in minimizing the firing of the ICD
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in patients with frequent events.1,10,16 Our data suggest that dmLSB is effective in eliminating
the arrhythmogenic substrate responsible for the Brugada syndrome and that it deserves further
study as a pharmacological adjunct to ICD usage.
Study Limitations
As with all in vitro experimental pharmacological models of human disease, caution must be
exercised in extrapolating the results to the clinic. Although our models closely resemble the
clinical syndrome with respect to ECG and arrhythmic manifestations, the full extent to which
the models predict the behavior of the various congenital forms of the Brugada syndrome
remains to be established.
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Recordings from canine arterially perfused right ventricular wedges. Transmembrane APs
recorded from 2 epicardial sites and 1 endocardial site together with a simultaneous ECG are
shown. A, Control followed by terfenadine (5 μmol/L) ±dmLSB (10 μmol/L). B, Control
followed by verapamil (5 μmol/L) ±dmLSB (10 μmol/L). C, Control followed by pinacidil (2
μmol/L) ±dmLSB (10 μmol/L). BCL=2000 ms.
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Epicardial notch parameters during control and Brugada syndrome model (terfenadine,
verapamil, or pinacidil) ±dmLSB (10 μmol/L). A, Notch magnitude [100 – (100 × phase 1
amplitude / phase 2 amplitude)]. B, Phase 0 to phase 2 (Ph 0 -Ph 2) interval (time between the
first 2 peaks of the derivative of the AP). C, Notch index (notch magnitude × Ph 0 – Ph 2
interval). BCL=2000 ms; n=9. Values are mean±SD. *P<0.05 vs control; †P<0.01 vs control;
‡P<0.001 vs control; **P<0.05 vs Brugada syndrome model; ††P<0.01 vs Brugada syndrome
model; ‡‡P<0.001 vs Brugada syndrome model.
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APD90 during control and after application of terfenadine (A; n=3), verapamil (B; n=3), and
pinacidil (C; n=3) with and without dmLSB (10 μmol/L). BCL=2000 ms. *P<0.05 vs control.
Endo indicates endocardial.
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Terfenadine (5 μmol/L; A; n=3), verapamil (1 to 5 μmol/L; B; n=3), and pinacidil (2 to 6
μmol/L; C; n=3) induce heterogeneous loss of the epicardial AP dome, producing both EDR
and TDR. D, Combined data for all 3 models (Brugada model, n=9). Addition of dmLSB (10
μmol/L) reduces dispersion in all 3 models. Values are mean±SD. *P<0.05 vs control; †P<0.01
vs control;‡P<0.001 vs control; **P<0.05 vs terfenadine, verapamil, pinacidil, or Brugada
syndrome model; ††P<0.01 vs terfenadine, verapamil, pinacidil, or Brugada syndrome model;
‡‡P<0.001 vs terfenadine, verapamil, pinacidil, or Brugada syndrome model.
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Phase 2 reentry induced in 3 separate models of the Brugada syndrome. Terfenadine (5 μmol/
L; A), verapamil (5 μmol/L; B), or pinacidil (6 μmol/L; C) induces heterogeneous loss of the
epicardial AP dome and ST-segment elevation. Phase 2 reentry occurs as the dome is
propagated from Epi 1 to Epi 2, triggering either a closely coupled extrasystole or polymorphic
VT. In all 3 models, addition of dmLSB (10 μmol/L) normalizes the ST segment and abolishes
phase 2 reentry and resultant arrhythmias. Endo indicates endocardial.
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Pinacidil (2 μmol/L) induces heterogeneous loss of the epicardial AP dome. Phase 2 reentry
occurs as the dome is propagated from Epi 1 to Epi 2, triggering an episode of polymorphic
VT (B). Addition of dmLSB (10 μmol/L) abolishes phase 2 reentry and polymorphic VT (C).
Endo indicates endocardial.
Fish et al. Page 13














Effect of dmLSB in the canine right ventricular wedge preparation. A, Transmural ECG and
APs recorded from 2 epicardial sites and 1 endocardial site (Endo) in a canine arterially
perfused wedge under control conditions and in the presence of dmLSB (0.5 to 20 μmol/L).
BCL=2000 ms. B, Effect of dmLSB (0.5 to 20 μmol/L) on the epicardial AP notch index (notch
magnitude × notch duration; see Figure 2 for complete definition). BCL=2000 ms; n=3. C,
Effect of dmLSB (0.5 to 20 μmol/L) on TDR and APD90 in 2 epicardial and 1 endocardial AP.
BCL=2000 ms; n=3.
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 Control 29.5± 4.1 39.0± 9.0 170.4± 384.5 28.1± 0.9 40.3± 4.4 1131.3± 88.9
 Terfenadine (5μ mol/L) 45.1± 6.6*no 45.2± 2.5 2046.9± 361.1*no 51.3± 10.9*no 48.9± 5.1 2538.9± 87.9
 +dmLSB (10 μ mol/L) 18.6± 3.4 24.1± 7.7§ 464.3± 237.4 23.8± 8.8§ 22.2± 15.4§ 597.5± 610.8§
Verapamil (n=3)
 Control 32.4± 0.9 44.9± 3.6 1790.0± 163.1 25.8± 4.1 34.5± 2.1 1685.6± 222.4
 Verapamil (1-5 μ mol/L) 59.5± 10.2 49.0± 3.3 3034.4± 559.6*no 50.6±11.4*no 48.2± 2.5 2634.8±693.3
 +dmLSB (10 μ mol/L) 18.4± 0.3§ 8.5± 4.6‡∥ 1687.1± 68.0¶ 21.1± 3.2¶ 24.1± 18.4 1624.1± 595.8
Pinacidil (n=3)
 Control 26.7± 7.8 35.1± 10.6 1681.5± 197.6 26.8± 8.4 31.1± 15.6 1765.7± 266.8
 Pinacidil (2-6μ mol/L) 49.6± 7.8 43.3± 10.3 2824.3± 787.7 51.3± 8.8*no 42.4± 7.1 2993.2±905.2
 +dmLSB (10 μ mol/L) 16.0±15.5§ 16.8± 18.1 1144.0±1027.8 5.6± 9.8 2.2± 3.7*no 527.8±914.1§
All (n=9)
 Control 29.6 ±5.1 39.6± 8.4 1204.9±136.8 26.9±4.8 35.3±9.1 978.1±398.4
 Brugada model 51.4±9.6‡ 45.9±6.1 2366.7± 602.9‡ 26.9±4.8‡ 35.3±9.1 2367.3±492.9†
 +dmLSB (10 μ mol/L) 17.7± 8.1*no∥
16.4






P< 0.05 vs control.
†P< 0.01 vs control.
‡
P< 0.001 vs control.
§
P<0.05 vs terfenadine, verapamil, pinacidil, or Brugada model.
∥
P < 0.01 vs terfenadine, verapamil, pinacidil, or Brugada model.
¶
P< 0.001 vs terfenadine, verapamil, pinacidil, or Brugada model.
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TABLE 2.
APD90 at Steady State (BCL=2000 ms)
Brugada Syndrome Model Epi 1 APD90, ms Epi 2 APD90, ms Endocardial APD90, ms
Terfenadine (n=3)
 Control 215.7± 9.7 213.2± 8.6 242.7± 11.6
 Terfenadine (5μ mol/L) 239.0±14.4 231.1± 12.4 251.8±6.4
 +dmLSB (10 μ mol/L) 212.8±13.2 202.3±6.9* 230.5±9.9
Verapamil (n=3)
 Control 240.2±19.4 223.0±18.4 249.0±12.1
 Verapamil (1-5 μ mol/L) 250.4 ±18.2 241.1± 5.4 265.4 ±4.2
 +dmLSB (10μ mol/L) 221.7±18.4 221.6±19.8 270.4±10.7
Pinacidil (n=3)
 Control 240.3±30.8 230.4± 22.5 279.0± 20.4
 Pinacidil (2-6μmol/L) 187.0± 17.5 172.9±17.6* 195.4± 38.3*
 +dmLSB (10 μ mol/L) 170.6±12.2* 163.0± 14.1* 218.0± 15.4
*
P< 0.05 vs control.
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TABLE 3.
Maximal EDR and TDR and Incidence of Arrhythmias
Brugada Syndrome Model EDR TDR Phase 2 Reentry Polymorphic VT
Terfenadine (n=3)
 Control 5.9± 3.2 15.2± 10.8 0/3 0/3
 Terfenadine (5 μ mol/L) 101.2±35.8 95.0± 32.7† 3/3 2/3
 +dmLSB (10μ mol/L) 3.8 ±0.1 6.1± 2.3∥ 0/3 0/3
Verapamil (n=3)
 Control 18.3± 7.6 17.9± 4.5 0/3 0/3
 Verapamil (1-5μ mol/L) 154.0± 66.1* 104.8± 40.5* 3/3 3/3
 +dmLSB (10μ mol/L) 24.4±30.3§ 39.6± 41.3 0/3 0/3
Pinacidil (n=3)
 Control 14.6± 13.6 29.8± 8.3 0/3 0/3
 pinacidil (2-6 μ mol/L) 66.4± 22.7* 46.8±1.0 3/3 1/3
 +dmLSB (10 μ mol/L) 9.1± 6.6§ 30.9± 16.8 0/3 0/3
All (n=9)
 Control 12.9± 9.6 22.4± 8.1 0/9 0/9
 Brugada model 107.2± 54.8* 82.2± 37.4‡ 9/9* 6/9




P < 0.01 vs control.
‡
P< 0.001 vs control.
§
P<0.05 vs terfenadine, verapamil, pinacidil, or Brugada model.
∥
P 0.01 vs terfenadine, verapamil, pinacidil, or Brugada model.
¶
P 0.001 vs terfenadine, verapamil, pinacidil, or Brugada model.
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